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ABSTRACT: Protein−protein interactions (PPIs) are an essential part of correct cellular
functionality, making them increasingly interesting drug targets. While Förster resonance
energy transfer-based methods have traditionally been widely used for PPI studies, label-free
techniques have recently drawn significant attention. These methods are ideal for studying
PPIs, most importantly as there is no need for labeling of either interaction partner, reducing
potential interferences and overall costs. Already, several different label-free methods are
available, such as differential scanning calorimetry and surface plasmon resonance, but these
biophysical methods suffer from low to medium throughput, which reduces suitability for
high-throughput screening (HTS) of PPI inhibitors. Differential scanning fluorimetry,
utilizing external fluorescent probes, is an HTS compatible technique, but high protein
concentration is needed for experiments. To improve the current concepts, we have
developed a method based on time-resolved luminescence, enabling PPI monitoring even at low nanomolar protein concentrations.
This method, called the protein probe technique, is based on a peptide conjugated with Eu3+ chelate, and it has already been applied
to monitor protein structural changes and small molecule interactions at elevated temperatures. Here, the applicability of the protein
probe technique was demonstrated by monitoring single-protein pairing and multiprotein complexes at room and elevated
temperatures. The concept functionality was proven by using both artificial and multiple natural protein pairs, such as KRAS and
eIF4A together with their binding partners, and C-reactive protein in a complex with its antibody.
Protein−protein interactions (PPI) are essential to thenormal function of a cell. The human genome can
produce over one million different proteins utilizing, e.g.,
alternative splicing and machinery related to post-translational
modifications.1 The vast majority of these proteins function as
a complex with one or more proteins. These complexes form
an interaction network by, e.g., adjusting enzyme activity
through signaling cascades, mediating physical motion through
actin and myosin, and controlling the cell cycle.2−4
In addition to providing insights into cellular processes, the
information on PPIs can also be applied for therapeutic
purposes.2,5 Historically, PPIs have been regarded as difficult
drug targets, mostly because the interacting regions of PPIs are
often flat and shallow, whereas small molecules often prefer
binding to well-defined pockets, as in the case of enzymes and
G-protein-coupled receptors, the most frequent drug targets
today. This lack of clearly defined binding pockets makes PPIs
difficult to target, especially for small molecule drugs. However,
advanced methods are developed constantly to identify new
ways to target PPIs. Such methodologies increase our
understanding of PPI properties, enabling the development
of novel types of drugs and mechanisms to control and study
clinically relevant PPIs. Especially, high-throughput screening
(HTS) methods are needed to effectively identify drug
candidates for different PPIs.6,7 As several methods are applied
in parallel to validate screened hits, any newly developed
methods can benefit the screening and validation process by
filling demands related to simplicity, assay time, and cost-
effectiveness.8,9
To this day, countless PPIs have been identified and studied
with several types of PPI analysis methods. Traditionally,
methods such as Förster resonance energy transfer (FRET),
which rely on labeling the interacting components, have been
extensively used to study PPIs also in a cellular context.10,11
However, labeling the interacting components may interfere
with the protein interactions. Thus, label-free methods have
attracted increasing interest, as the interacting components are
not labeled, providing increased flexibility for the detection of
different PPI pairs and also new targets. These methods can be
roughly divided as biophysical and luminescence-based
methods.
Biophysical methods give information on, e.g., biomolecular
structures and their dynamics and function, and the gold
standard for PPIs and their interaction thermodynamics
Received: July 2, 2020
Accepted: November 17, 2020
Published: November 25, 2020
Articlepubs.acs.org/ac
© 2020 American Chemical Society
15781
https://dx.doi.org/10.1021/acs.analchem.0c02823
Anal. Chem. 2020, 92, 15781−15788
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,


























































































monitoring is calorimetry. Both isothermal titration calorim-
etry and differential scanning calorimetry are often applied for
PPIs,12 but the disadvantage for these methods is the need for
a relatively high micromolar protein concentration. Experi-
ments are also delicate and is run in a carefully optimized and
controlled environment. In addition, these methods are
typically performed for individual samples, which is suboptimal
for HTS.12−16 Surface plasmon resonance (SPR) is another
widely used technique originally developed for PPI studies.
SPR has a relatively high sensitivity and is applicable to a large
variety of different types of molecules within a wide
concentration range. In SPR, one binding partner is
immobilized onto the sensor surface, resembling a labeling
procedure with similar potential problems. Even though SPR
has higher throughput compared to the calorimetric methods,
it is still not counted as a full HTS method. Regardless of the
deficiencies, SPR is useful especially for fragment-based
screening with a limited compound library size.17,18
Luminescence-based label-free methods utilize external
probes and environmentally sensitive labels for detection.
One of the main motivations for developing these methods has
been the improved applicability for HTS compared to
biophysical techniques. One such method is differential
scanning fluorimetry (DSF), which relies on environmentally
sensitive dyes to monitor the thermal stability of the studied
protein in the presence and absence of interacting small
molecular ligands (protein−ligand interaction, PLI) or
proteins (PPI). SYPRO Orange is the most frequently used
DSF dye today, as its spectral properties directly match the
general laboratory hardware. SYPRO Orange luminescence is
heavily quenched by water, but upon target protein
denaturation, it binds to hydrophobic patches of the target
protein. This binding-driven protection of SYPRO Orange
increases the quantum yield, monitored as an increase in
fluorescence.19−21 Other dyes such as ANS (8-anilino-1-
naphthalenesulfonic acid) and Nile Red have also been utilized
in DSF measurements. These alternative dyes function highly
similarly to SYPRO Orange, although, e.g., ANS has been
reported to also interact with the cationic parts of the target
protein.21−24 Similar to differential scanning calorimetry, DSF
monitors PPIs based on the thermal stability changes upon
interaction. The main advantage of the DSF measurements
over calorimetry is the HTS compatibility on a microtiter plate
format.19,20,25 The disadvantages are that not all PPIs provide a
measurable thermal shift upon binding and that the DSF
methods are material-consuming. The use of micromolar
protein concentrations increases the risk of artifacts related to,
e.g., spontaneous protein aggregation, simultaneously increas-
ing the assay costs. Therefore, there has been an increasing
need for more sensitive label-free probes with improved
detection sensitivity and applicability to the HTS environment.
We have previously studied protein−protein interactions
using time-resolved FRET (TR-FRET) and developed a
quencher-modulated TR-FRET method enabling simultaneous
monitoring of both PLI and PPI reactions.26 In addition, we
have recently introduced an external Eu3+-labeled protein
probe technique for the detection of protein stability and PLIs
at a low nanomolar sensitivity level.27 In this study, we
introduce a further development of the protein probe for the
detection of PPIs. The method is applicable not only for
thermal but also for isothermal PPI detection, depending on
the nature of the studied proteins or protein complexes. The
label-free assay is HTS-compatible as performed in a microtiter
plate format, and the simplicity of the method was highlighted
using different disease relevant model PPI pairs, e.g., eukaryotic
initiation factor 4A (eIF4A) and KRAS.
■ EXPERIMENTAL SECTION
The detailed list of materials and instrumentation, production
and purification of proteins, Eu3+ conjugations, assay
optimization, control assays, and data analysis are presented
in the Supporting Information (SI). In addition, detailed
protocols for model PPI reactions performed either at room
temperature (RT) (streptavidin (SA)−biotinylated bovine
serum albumin (BSA) and C-reactive protein (CRP)−
monoclonal antibody (mAb)) or at elevated temperatures
(CRP−mAb, KRAS−K27, and eukaryotic initiation factor 4A
(eIF4A) either with eukaryotic translation initiation factor
(eIF4H) or programmed cell death protein 4 (PDCD4)) are
presented in the Supporting Information.
■ RESULTS AND DISCUSSION
Interactions between proteins are a fundamental part of correct
cellular functionality, and impaired interactions may lead to
various disease states. We have previously developed a label-
free method for the detection of protein stability and PLIs,27
which we now apply for PPI monitoring. The protein probe
technique is based on a negatively charged Eu3+ chelate-labeled
peptide (Eu3+ probe) used to measure protein structural
changes, such as an increased surface area and exposed
hydrophobic regions. Here, we introduce the protein probe
technique in the context of PPIs (Figure 1), with the same
Eu3+ probe in conditions optimized for PPI monitoring. The
spectral studies of the Eu3+ probe and modulator showed the
typical time-resolved luminescence (TRL) emission spectrum
of the Eu3+ probe overlapping with the modulator excitation
spectrum supplemented in the protein probe solution (Figure
S1A). In the presence of two non-interacting proteins, the
protein probe TRL signal is low, as the Eu3+ probe has a
negligible interaction with intact individual proteins, leading to
a considerably shortened luminescence lifetime (Figure S1B).
However, upon protein pairing, the Eu3+ probe nanoenviron-
ment changes, providing a contact surface for the Eu3+ probe
binding. This results in an increased monitored TRL signal at
room temperature (RT) or at elevated temperatures, depend-
ing on the size of the studied interaction complex.
Proof-of-Concept Streptavidin/Bio-BSA Assay Dem-
onstrates the Protein Probe Technique for PPI
Monitoring. PPIs are relatively difficult to monitor without
excessive labeling and/or surface conjugation, and often they
occur at a micromolar affinity level. To test the protein probe
technique for PPI monitoring, we first selected model proteins
with engineered interaction of unusually high binding affinity.
Bio-BSA and SA, which form a large protein complex, were
investigated as a proof-of-concept artificial protein pair. This
ultrahigh affinity interaction enables, and also ensures, a
maximal and basically irreversible binding, which is ideal for
the assay demonstration.28 To study this, 20 nM BSA or bio-
BSA were assayed in an SA titration (10−600 nM). Under
these conditions, no SA concentration-dependent TRL signal
change was detected with non-interacting BSA (Figure 2A).
However, a clear increase in the TRL signal was detected with
bio-BSA when monitored under the same conditions at RT.
The maximal signal was achieved at a 200 nM SA
concentration, and no further signal change was observed at
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higher SA concentrations. This indicates that the increased
molecular weight and/or the nature of the formed complex had
an impact on the binding properties of the Eu3+ probe and the
detected TRL signal.
To prove the functionality, we next tested blocking the SA
and bio-BSA interaction by performing biotin titration (0.01−
10 μM). The assay was carried out with 200 nM SA and 20 nM
bio-BSA, giving the maximal signal. We observed a biotin
concentration-dependent reduction of the TRL signal with an
S/B ratio of 34 calculated from the reactions with or without
biotin (Figure 2B). This indicates the expected loss of bio-BSA
interaction with SA in the presence of biotin. The observed
IC50 value of 306 ± 4 nM is in accordance with the given SA
concentration and demonstrates that the TRL signal response
monitored was due to the artificial protein complexation,
impaired by free biotin.
Antibody−Antigen Interaction at RT Is Detected
Using the Protein Probe Technique. As the artificial
model with SA and bio-BSA indicated protein probe
functionality in PPI, we next studied a second high affinity
PPI model: CRP interaction with anti-CRP mAb. CRP (0−100
nM) was first assayed with an anti-CRP mAb (0−500 nM) and
also with two nonspecific mAbs as controls. The selected anti-
CRP mAb has an ultrahigh picomolar level affinity for CRP
binding.29 Similar to the bio-BSA/SA pair, the binding
between CRP and the specific anti-CRP mAb resulted in an
increase in the TRL-signal at RT, whereas the nonspecific
mAbs had no significant impact on the signal (Figure 3, Figure
S2). Within the studied concentration ranges, the observed
TRL signal between the protein complex and mAb alone
peaked at the approximate ratio of 5:1 (mAb/CRP)
independent of the protein concentration level. This is not
surprising as CRP is known to have a pentameric structure.
The maximal S/B ratio of 4.3, mAb/CRP complex vs mAb,
was achieved with 20 nM CRP and 100 nM anti-CRP mAb, as
at higher concentrations, the individual proteins already
showed a minor increase in the signal without complexation
(Figure S2). Also, this PPI model indicates that the relatively
large protein complex provides a sufficient TRL signal change
with the studied model systems when monitored at RT.
The Protein Probe Technique Measures Antibody−
Antigen Interaction at Elevated Temperatures. Iso-
thermal studies with the protein probe demonstrated that
Figure 1. Protein-Probe technique for label-free protein−protein
interaction monitoring. (A) Protein-Probe shows negligible binding to
individual intact low-concentration proteins at room temperature
(RT), monitored as a low TRL signal. (B) When the Protein-Probe is
utilized for the detection of a large multiprotein complex, here, C-
reactive protein (CRP) with its antibodies, the Eu3+ probe senses the
increased surface area and a high TRL signal is observed at RT. (C)
In the case of smaller proteins forming a 1:1 complex, a low TRL
signal is monitored at RT, as the interaction cannot reshape the
proteins sufficiently for Protein-Probe sensing. (D) However, upon
heating, the protein−protein complex becomes more accessible for
the Eu3+ probe binding, and the formation of a protein−protein pair is
visible from the increase in the TRL signal and/or change in thermal
stability.
Figure 2. Bio-BSA interaction with streptavidin (SA) can be monitored using the Protein-Probe assay platform. (A) Assay performed with 20 nM
BSA (red) or bio-BSA (black) and SA (10−600 nM) showed a clear increase in the TRL signal only in the case of bio-BSA, when monitored 5 min
after the addition of the protein probe at RT. (B) Adding biotin (0.01−10 μM) reduced the TRL signal in the assay with 200 nM SA and 20 nM
bio-BSA. This demonstrates the disintegration of the interaction between SA and bio-BSA when monitored at RT. Data from a single representative
assay showing individual reactions (mean ± SD, n = 3).
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large complexes can be monitored at RT. Next, we tested the
effect of elevated temperatures on the performance of the
protein probe method by assaying CRP and mAb individually
and in a complex for changes in the melting temperature (Tm).
We have previously shown that an increase in the TRL signal is
observed when a heated and denatured protein sample is
monitored with the protein probe method, and we expected to
measure an improved detectability with PPIs.27 In all assays,
the reactions are performed in biologically relevant buffers at
RT, and thereafter the protein complex is heated to a given
temperature. For the detection, the protein solution is reverted
to RT by adding the protein probe solution.
We started the studies at elevated temperatures by
determining the effect of mAb concentration to the signal
and Tm (Figure S3). Although the mAb concentration had a
drastic effect on the TRL signal level (Figure S3A), no major
effect on Tm was observed at the measured concentration range
(0.5−120 nM) (Figure S3B). Keeping in mind the signal level
at RT and heating, we next tested the anti-CRP mAb (30 nM)
and multiple CRP concentrations (0−150 nM) to observe the
optimal protein ratio (Figure S4). The individually assayed two
CRP concentrations (50 and 150 nM) and 30 nM mAb in
complex with 150 nM CRP gave highly similar temperature
profiles with Tm values of 56.0 ± 0.5, 58.8 ± 0.2, and 56.0 ±
1.0 °C, respectively. These values clearly follow the CRP
melting without any significant information on the interaction.
On the other hand, the lowest CRP concentration (5 nM)
combined with mAb resulted in a similar Tm to mAb alone:
76.9 ± 1.0 and 77.8 ± 0.2 °C, respectively. No melting curve
could be measured for 5 nM CRP. Interestingly, 50 nM CRP
assayed with mAb gave a two-phase melting curve with Tm
values of 58.1 ± 1.2 and 69.2 ± 0.4 °C. The first phase relates
CRP melting, whereas the Tm of the second phase indicates
CRP interaction with anti-CRP mAb (Figure S4A).
Unfortunately, the results obtained with mAb and various
CRP concentrations provided no conclusive information on
whether the binding has a measurable impact on the melting
curve. Thus, we hypothesized that these concentrations might
be too high to enable complex monitoring at elevated
temperatures. To study this further, we selected two mAb
concentrations (2 nM or 10 nM), which we assayed alone or
with 1 and 5 nM or 5 and 10 nM CRP, respectively. At these
concentrations, CRP was undetectable and mAb gave some
measurable TRL signal (Figure S3). As hypothesized, a 4.2-
fold TRL signal was measured when 2 nM mAb was assayed
with 5 nM CRP and compared to the mAb alone at 90 °C
(data not shown). This indicates that the interaction was
detected, although the calculated Tm for mAb alone compared
to in complex with CRP showed only a minor increase from
76.8 ± 0.1 to 79.1 ± 0.1 °C, respectively (data not shown). To
study this further, we performed the assay using 10 nM anti-
CRP mAb and nonspecific anti-hemoglobin mAb as the
control. Both mAbs were assayed with 5 and 10 nM CRP
(Figure S4B). At these concentrations, both mAbs were
detectable, but the complex formation was monitored
specifically with anti-CRP mAb and not with the nonspecific
control. The signal increase with anti-CRP mAb was 7.4-fold
with 5 nM CRP and 4.0-fold with 10 nM CRP, compared to
nonspecific antihemoglobin mAb at 90 °C (Figure S4B). This
indicates that the interaction was measurable at elevated
temperatures for this stable, high-affinity antibody−antigen
complex.
The Protein Probe Technique Monitors eIF4A
Interaction at Elevated Temperatures. Following the
CRP/mAb study, we chose to investigate more traditional PPI
pairs with a significantly lower binding affinity. We selected
eIF4A1 as the first target and monitored its interactions with
two known binding partners, PDCD4 and eIF4H. eIF4A is a
core translation initiation factor linking its ATPase activity to
RNA helicase activity. It is a vital part of the eIF4F mRNA-cap-
binding complex together with eIF4G and eIF4E, functioning
as a main helicase in translation initiation.30 eIF4A activity is
modulated most notably by eIF4G, a scaffolding protein, and
cofactor proteins eIF4H and eIF4B, which increase the helicase
activity.30,31 PDCD4, on the other hand, reduces eIF4A
activity by blocking the RNA binding to the helicase and
Figure 3. Protein probe technique can monitor CRP interaction with anti-CRP mAb at room temperature. (A) Interaction with CRP (0−100 nM)
was monitored in titration with single anti-CRP mAb (0−500 nM) at RT. The optimal S/B ratio (mAb/CRP vs mAb) was obtained at a mAb/
CRP ratio of 5:1, and the highest S/B ratio was obtained with 20 nM CRP and 100 nM mAb. (B) Nonspecific mAbs resulted in an insignificant
signal change compared to CRP alone, as expected with no interaction. The TRL signals of the two nonspecific mAbs were highly similar
(presented with error bars). Data are presented as an S/B ratio calculated from average signals (n = 3).
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competing with eIF4G.32,33 As eIF4H and PDCD4 differ in
molecular weight, binding mode, and affinity to eIF4A,34−37 we
selected these two eIF4A-binding proteins to perform further
studies with the protein probe technique.
Before conducting any binding assays, we determined the
eIF4A functionality in a helicase assay with and without eIF4H
and PDCD4 to ensure the protein quality and binding
capacity. eIF4A was monitored with an equal amount of
eIF4H using preannealed Cy3- and BHQ2-RNA and in the
presence of excess DNA.38,39 The eIF4H-induced increase in
the eIF4A helicase activity was measured as an elevated FRET
signal (Figure S5A). PDCD4 inhibitory activity was monitored
in a similar assay using a 1:1 eIF4A:eIF4H complex in PDCD4
titration, and the monitored IC50 was 330 ± 8 nM for PDCD4
(Figure S5B). As all proteins showed expected functionality,
we next determined the signal level and thermal stability
properties of the individual proteins. Thermal melting assays
were performed both with the protein probe and SYPRO
Orange (Figure S6), and as previously,27 the protein probe
assays could be performed at lower concentrations compared
to SYPRO Orange. The Tm values measured for eIF4A with
the protein probe and SYPRO Orange were 54.5 ± 0.1 and
50.3 ± 0.1 °C, respectively.40 In addition, we found that eIF4A
detectability with the protein probe technique was improved
by using Triton X-100 in the assay buffer. When the melting
curve of 75 nM eIF4A was monitored using the protein probe
without and with 0.001% Triton X-100, the S/B ratio at 65 °C
was increased from 2.9 to 32.3, respectively. The correspond-
ing Tm values were also monitored for PDCD4 and eIF4H. For
PDCD4, Tm values were 59.7 ± 0.1 and 60.0 ± 0.3 °C with the
protein probe and SYPRO Orange methods, respectively (data
not shown). However, the results with eIF4H were non-
conclusive with either method, and no clear thermal curve was
detected (data not shown). To our knowledge, there are no
reported Tm values for eIF4H and PDCD4.
As the affinity between eIF4A and the two selected
interaction partners is in the submicromolar to micromolar
level,35−37 we selected 75 nM eIF4A1 to monitor interaction
with eIF4H and PDCD4. Assays were performed in a buffer
without Triton X-100, to reduce the assay sensitivity and to
enable the use of higher protein concentrations. This selection
was based on the mAb/CRP observation at high vs low
concentrations (Figure S4). The thermal ramping with eIF4A
was then performed using eIF4H and PDCD4 concentrations
up to 1000 nM and 300 nM, respectively. Again, the
interactions were carried out at RT before the complexes
were heated. At the tested concentrations, eIF4H and PDCD4
gave only a modest signal when individual proteins were
measured. However, when they were assayed in complex with
eIF4A, a clear TRL signal increase was detected at elevated
temperatures (Figure 4). Both protein complexes resulted in
the highest S/B ratio at 65 °C when the complex was
compared to individual eIF4H and PDCD4. S/B ratios of 5.5
and 4.0 were calculated for eIF4A interaction with 500 and
1000 nM eIF4H, respectively. PDCD4/eIF4A interaction was
observed already at a 1:1 (75 nM) complex, but the interaction
with higher (150 and 300 nM) PDCD4 concentrations
resulted in increased S/B ratios of 10.5 and 5.0, respectively.
In these assays, the monitored Tm value mostly followed the
Tm of eIF4A alone, as the Tm values monitored with eIF4H
and PDCD4 were 55.0 ± 0.2 and 56.4 ± 0.8 °C, respectively.
Thus, ΔT of 0.5 and 1.9 °C were detected with eIF4H and
PDCD4, respectively. As a control, 500 nM eIF4H and 150
nM PDCD4 were measured together at elevated temperatures
(Figure S7). These proteins do not interact, and thus the S/B
ratio of the complex did not significantly exceed that of the
individual proteins when compared to the protein probe
solution in buffer. This confirms that the measured PPI is
specific in nature, and the TRL signal increase is not due to the
revealed hydrophobic areas of the partially unfolded proteins
or the increase in total protein concentration. The results also
demonstrate that it is possible to monitor individual PPIs that
have binding affinities in the common range for PPIs, even
with relatively small proteins of different sizes (MW ranging
from 27.4 to 51.7 kDa) without forming large multiprotein
complexes.
Figure 4. eIF4A interaction with eIF4H and PDCD4 could be detected using the protein probe technique. (A) Interaction between 75 nM eIF4A
and 0.5 or 1 μM eIF4H was monitored in thermal ramping. eIF4A yielded no TRL signal and eIF4H yielded a low TRL signal when they were
measured individually, but with an eIF4A/eIF4H complex, a high TRL signal was monitored at increased temperatures. (B) Interaction of 75 nM
eIF4A and 75−300 nM PDCD4 was similarly observed as an increase in the TRL signal at elevated temperatures. At these concentrations, proteins
did not produce thermal curves alone but only in complex. Data from a single representative assay showing individual reactions (mean ± SD, n =
3).
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KRAS Thermal Stabilization with DARPin K27 Is
Observed with the Protein Probe Technique. Many
interactions have been reported to produce a significant
stabilizing effect in complex with a binding partner when
compared to individual proteins, and the strategy has been
successfully applied especially in PLI inhibitor screening.41,42
We did not observe any major thermal shift with eIF4A and its
binding partners, and thus we next chose to investigate KRAS,
which is reported to be responsive to thermal stabilization.43
As a KRAS interaction partner, we selected a guanosine
diphosphate (GDP)-KRAS-specific designed ankyrin repeat
protein (DARPin), K27, which is known to have inhibitory
properties on KRAS activation and interactions with other
proteins.44 First, to prove the specificity and to estimate the
binding affinity of K27 for KRAS, a quenching resonance
energy transfer nucleotide exchange assay was performed using
50 nM KRAS.26,45,46 Based on these results, IC50 values close
to the KRAS concentration were calculated for K27 and also
for GDP acting as a control (Figure S8). As only GDP showed
a clear inhibitory curve with 5′-guanylyl imidodiphosphate
(GMPPNP)-loaded KRAS, the results indicate that the affinity
value for K27 is below 50 nM for GDP-KRAS and is
significantly higher for GMPPNP-KRAS, which can thus be
used as a control in interaction studies (Figure S8).44
As with eIF4A, KRAS was first studied using the protein
probe side-by-side with SYPRO Orange to determine the
appropriate concentration level for each individual method
(Figure S9). Based on these experiments, we selected 50 nM
KRAS for the protein probe interaction studies with K27. K27
yielded only low TRL signals at elevated temperatures due to
its high thermal stability.47 KRAS loaded with GDP or
GMPPNP were next measured with the protein probe or
SYPRO Orange in thermal denaturation. The calculated Tm
values of 50 nM KRAS with the protein probe were 62.7 ± 0.3
and 53.0 ± 0.4 °C for GDP- and GMPPNP-KRAS, respectively
(Figure 5). These Tm values were further confirmed with
SYPRO Orange using 3 μM KRAS, giving Tm values of 58.6 ±
0.4 and 50.1 ± 0.6 °C for GDP- and GMPPNP-KRAS,
respectively (data not shown). As K27 affinity was at a low
nanomolar level (Figure S8), we selected 100 nM K27 for
interaction assays with KRAS. This concentration is expected
to provide near complete saturation and thus enables high
response when interacting with KRAS. In a thermal assay with
the protein probe, a K27-dependent Tm shift in the KRAS
denaturation curve was monitored with GDP-KRAS but not
with the GMPPNP-KRAS used as a control (Figure 5). ΔT
monitored with GDP-KRAS was 8.7 °C, whereas with
GMPPNP-KRAS it was negligible (0.3 °C). This thermal
shift demonstrates K27-specific interaction with GDP-KRAS,
and that the KRAS is thermally stabilized upon interaction.
These results were further confirmed using SYPRO Orange
(data not shown), and together, these results demonstrate the
potential of the protein probe technique to monitor different
types of PPIs.
Here, we presented the protein probe technique for the
monitoring of PPIs possessing binding affinities from the
picomolar to micromolar level. The method can be applied for
the detection of dimeric and multimeric interactions at room
and elevated temperatures. All interactions were performed at
RT, but with smaller protein pairs of a relatively small size, the
complex formation can be detected by taking advantage of the
increasing temperature. Using the eIF4A translation initiation
factor, we demonstrated that PPIs occurring without significant
thermal stabilization can also be monitored. On the other
hand, the ability to monitor KRAS thermal stabilization was
demonstrated in the presence of K27 DARPin. With both
natural and artificial model systems, we were able to
demonstrate PPI monitoring using multiple different concepts
by varying the temperature and adjusting the protein
concentration to an appropriate level to support each detection
method. Further studies are needed to prove the assay
functionality as an HTS tool for PPI inhibitor screening and
for alternative type PPI formats. However, the functionality in
the microtiter plate format provides a good starting point for
these assays and for further studies to understand the
mechanism behind the method to improve its function.
■ CONCLUSIONS
We have demonstrated the applicability of the protein probe
for PPI monitoring using nanomolar protein concentrations
and various protein pairs with different binding properties. The
external Eu3+ probe differentiates individual and interacting
proteins by providing high TRL signals after protein−protein
complexation. The protein probe was demonstrated to detect
PPIs at room and elevated temperatures depending on the
protein complex. The method was shown to have high
sensitivity compared to reference methods, enabling lowered
protein consumption and thus leading to less expensive assays
with a lower risk of aggregation-mediated artifacts. The
method can potentially be used for general protein interaction
studies and, after careful studies to prove the method
robustness, also for PPI inhibitor screening in an HTS format.
In the future, the protein probe method is also expected to
provide an efficient tool for monitoring other types of
interactions, e.g., protein aggregation.
Figure 5. KRAS stability increase upon K27 DARPin interaction
monitored with the protein probe assay. KRAS (50 nM) loaded with
GMPPNP and GDP were monitored individually or in the complex
with 100 nM K27, a GDP-KRAS-specific DARPin. The GMPPNP-
KRAS Tm was not affected by K27, whereas the stability of GDP-
KRAS was increased significantly, ΔT = 8.7 °C. K27 did not produce
a signal at the elevated temperature. Data from a single representative
assay showing individual reactions (mean ± SD, n = 3).
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